Literature DB >> 28288952

Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.

Aaron T Gerds1, Kwang Woo Ahn2, Zhen-Huan Hu3, Hisham Abdel-Azim4, Gorgun Akpek5, Mahmoud Aljurf6, Karen K Ballen7, Amer Beitinjaneh8, Ulrike Bacher9, Jean-Yves Cahn10, Saurabh Chhabra3, Corey Cutler11, Andrew Daly12, Zachariah DeFilipp7, Robert Peter Gale13, Usama Gergis14, Michael R Grunwald15, Gregory A Hale16, Betty Ky Hamilton17, Madan Jagasia18, Rammurti T Kamble19, Tamila Kindwall-Keller20, Taiga Nishihori21, Richard F Olsson22, Muthalagu Ramanathan23, Ayman A Saad24, Melhem Solh25, Celalettin Ustun26, David Valcárcel27, Erica Warlick26, Baldeep M Wirk28, Matt Kalaycio29, Edwin Alyea11, Uday Popat30, Ronald Sobecks29, Wael Saber3.   

Abstract

For patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, umbilical cord blood transplantation (UCBT) has become an acceptable alternative donor source in the absence of a matched sibling or unrelated donor. To date, however, there have been few published series dedicated solely to describing the outcomes of adult patients with myelodysplastic syndrome (MDS) who have undergone UCBT. Between 2004 and 2013, 176 adults with MDS underwent UCBT as reported to the Center for International Blood and Marrow Transplant Research. Median age at the time of transplantation was 56 years (range, 18-73 years). The study group included 10% with very low, 23% with low, 19% with intermediate, 19% with high, and 13% with very high-risk Revised International Prognostic Scoring System (IPSS-R) scores. The 100-day probability of grade II-IV acute graft-versus-host disease (GVHD) was 38%, and the 3-year probability of chronic GVHD was 28%. The probabilities of relapse and transplantation-related mortality (TRM) at 3 years were 32% and 40%, respectively, leading to a 3-year disease-free survival (DFS) of 28% and an overall survival (OS) of 31%. In multivariate analysis, increasing IPSS-R score at the time of HCT was associated with inferior TRM (P = .0056), DFS (P = .018), and OS (P = .0082), but not with GVHD or relapse. The presence of pretransplantation comorbidities was associated with TRM (P = .001), DFS (P = .02), and OS (P = .001). Reduced-intensity conditioning was associated with increased risk of relapse (relative risk, 3.95; 95% confidence interval, 1.78-8.75; P < .001), and although a higher proportion of myeloablative UCBTs were performed in patients with high-risk disease, the effect of conditioning regimen intensity was the same regardless of IPSS-R score. For some individuals who lack a matched sibling or unrelated donor, UCBT can result in long-term DFS; however, the success of UCBT in this population is hampered by a high rate of TRM.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Blood and marrow transplantation; Myelodysplastic syndrome; Umbilical cord transplantation

Mesh:

Year:  2017        PMID: 28288952      PMCID: PMC5474679          DOI: 10.1016/j.bbmt.2017.03.014

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  31 in total

1.  The role of registries in facilitating clinical research in BMT: examples from the Center for International Blood and Marrow Transplant Research.

Authors:  Mm Horowitz
Journal:  Bone Marrow Transplant       Date:  2008-08       Impact factor: 5.483

2.  Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies.

Authors:  David Avigan; Parameswaran Hari; Minoo Battiwalla; Michael R Bishop; Sergio A Giralt; Nancy M Hardy; Nicolaus Kröger; Alan S Wayne; Katharine C Hsu
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-07       Impact factor: 5.742

3.  Pursuing the goal of a donor for everyone in need.

Authors:  Frederick R Appelbaum
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

4.  Unrelated cord blood transplantation after myeloablative conditioning in adults with advanced myelodysplastic syndromes.

Authors:  A Sato; J Ooi; S Takahashi; N Tsukada; S Kato; T Kawakita; T Yagyu; F Nagamura; T Iseki; A Tojo; S Asano
Journal:  Bone Marrow Transplant       Date:  2010-04-19       Impact factor: 5.483

Review 5.  Transplantation for myelodysplastic syndrome in the era of hypomethylating agents.

Authors:  Aaron T Gerds; H Joachim Deeg
Journal:  Curr Opin Hematol       Date:  2012-03       Impact factor: 3.284

6.  Quantification of the completeness of follow-up.

Authors:  Taane G Clark; Douglas G Altman; Bianca L De Stavola
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

7.  Ex Vivo Expansion or Manipulation of Stem Cells to Improve Outcome of Umbilical Cord Blood Transplantation.

Authors:  Mitchell E Horwitz
Journal:  Curr Hematol Malig Rep       Date:  2016-02       Impact factor: 3.952

8.  Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

Authors:  Brian C Shaffer; Kwang Woo Ahn; Zhen-Huan Hu; Taiga Nishihori; Adriana K Malone; David Valcárcel; Michael R Grunwald; Ulrike Bacher; Betty Hamilton; Mohamed A Kharfan-Dabaja; Ayman Saad; Corey Cutler; Erica Warlick; Ran Reshef; Baldeep Mona Wirk; Mitchell Sabloff; Omotayo Fasan; Aaron Gerds; David Marks; Richard Olsson; William Allen Wood; Luciano J Costa; Alan M Miller; Jorge Cortes; Andrew Daly; Tamila L Kindwall-Keller; Rammurti Kamble; David A Rizzieri; Jean-Yves Cahn; Robert Peter Gale; Basem William; Mark Litzow; Peter H Wiernik; Jane Liesveld; Bipin N Savani; Ravi Vij; Celalettin Ustun; Edward Copelan; Uday Popat; Matt Kalaycio; Richard Maziarz; Edwin Alyea; Ron Sobecks; Steven Pavletic; Martin Tallman; Wael Saber
Journal:  J Clin Oncol       Date:  2016-04-04       Impact factor: 44.544

9.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

10.  A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.

Authors:  Corey S Cutler; Stephanie J Lee; Peter Greenberg; H Joachim Deeg; Waleska S Pérez; Claudio Anasetti; Brian J Bolwell; Mitchell S Cairo; Robert Peter Gale; John P Klein; Hillard M Lazarus; Jane L Liesveld; Philip L McCarthy; Gustavo A Milone; J Douglas Rizzo; Kirk R Schultz; Michael E Trigg; Armand Keating; Daniel J Weisdorf; Joseph H Antin; Mary M Horowitz
Journal:  Blood       Date:  2004-03-23       Impact factor: 22.113

View more
  8 in total

Review 1.  Cord blood transplantation for bone marrow failure syndromes: state of art.

Authors:  Simona Pagliuca; Annalisa Ruggeri; Régis Peffault de Latour
Journal:  Stem Cell Investig       Date:  2019-12-05

Review 2.  From patient centered risk factors to comprehensive prognostic models: a suggested framework for outcome prediction in umbilical cord blood transplantation.

Authors:  Roni Shouval; Arnon Nagler
Journal:  Stem Cell Investig       Date:  2017-05-24

3.  Existing agents, novel agents, or transplantation for high-risk MDS.

Authors:  Bart L Scott
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

4.  Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Monzr M Al Malki; Nitya Nathwani; Dongyun Yang; Saro Armenian; Sanjeet Dadwal; Jaroslava Salman; Sally Mokhtari; Thai Cao; Karamjeet Sandhu; Michelle Rouse; Matthew Mei; Haris Ali; Pablo Parker; Joseph Alvarnas; Eileen Smith; Margaret O Donnell; Guido Marcucci; David Snyder; Auayporn Nademanee; Stephen J Forman; Anthony Stein; Ryotaro Nakamura
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-09       Impact factor: 5.742

5.  Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell Transplantation.

Authors:  Ken Ishiyama; Jun Aoki; Hidehiro Itonaga; Naoyuki Uchida; Satoshi Takahashi; Yuju Ohno; Yoshiko Matsuhashi; Toru Sakura; Makoto Onizuka; Shigesaburo Miyakoshi; Minoko Takanashi; Takahiro Fukuda; Yoshiko Atsuta; Shinji Nakao; Yasushi Miyazaki
Journal:  Blood Cancer J       Date:  2019-03-06       Impact factor: 11.037

Review 6.  BMT for Myelodysplastic Syndrome: When and Where and How.

Authors:  Akriti G Jain; Hany Elmariah
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

7.  Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.

Authors:  Ryotaro Nakamura; Wael Saber; Michael J Martens; Alyssa Ramirez; Bart Scott; Betul Oran; Eric Leifer; Roni Tamari; Asmita Mishra; Richard T Maziarz; Joseph McGuirk; Peter Westervelt; Sumithira Vasu; Mrinal Patnaik; Rammurti Kamble; Stephen J Forman; Mikkael A Sekeres; Frederick Appelbaum; Adam Mendizabal; Brent Logan; Mary Horowitz; Corey Cutler
Journal:  J Clin Oncol       Date:  2021-06-09       Impact factor: 50.717

Review 8.  Umbilical cord blood transplantation: Still growing and improving.

Authors:  Xiaoyu Zhu; Baolin Tang; Zimin Sun
Journal:  Stem Cells Transl Med       Date:  2021-11       Impact factor: 6.940

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.